Literature DB >> 15661260

Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia.

Stephanie R Fink1, Sarah F Paternoster, Stephanie A Smoley, Heather C Flynn, Susan M Geyer, Tait D Shanafelt, You Kyoung Lee, Diane F Jelinek, Neil E Kay, Gordon W Dewald.   

Abstract

Fluorescent-labeled DNA probes were used to study 52 chronic lymphocytic leukemia (B-CLL) patients for (1) disease progression, (2) angiogenesis genes, (3) T-cell leukemia 1 gene (TCL1), (4) immunoglobulin heavy chain variable region (IGHv) and (5) chromosome 6q. Compared to stable disease, more patients with progressive disease had > or =2 anomalies and a high percentage of neoplastic nuclei. Anomalies of genes for basic fibroblast growth factor, interleukin 4, vascular endothelial growth factor or TCL1 were not detected. Deletions in IGHv occurred in 25% of patients and correlated with IGHv gene expression. Probes for 6q23 detected more deletions in 6q than probes for 6q21.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15661260     DOI： 10.1016/j.leukres.2004.07.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  7 in total

1.  Telomeric IGH losses detectable by fluorescence in situ hybridization in chronic lymphocytic leukemia reflect somatic VH recombination events.

Authors:  Iwona Wlodarska; Christine Matthews; Ellen Veyt; Helena Pospisilova; Mark A Catherwood; Tim S Poulsen; Vera Vanhentenrijk; Rachel Ibbotson; Peter Vandenberghe; T C M Curly Morris; H Denis Alexander
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

2.  The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.

Authors:  E Vasyutina; J M Boucas; J Bloehdorn; C Aszyk; G Crispatzu; M Stiefelhagen; A Breuer; P Mayer; C Lengerke; H Döhner; D Beutner; A Rosenwald; S Stilgenbauer; M Hallek; A Benner; M Herling
Journal:  Leukemia       Date:  2015-05-04       Impact factor: 11.528

3.  Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium.

Authors:  Stephanie A Smoley; Daniel L Van Dyke; Neil E Kay; Nyla A Heerema; Marie L Dell' Aquila; Paola Dal Cin; Prasad Koduru; Ayala Aviram; Laura Rassenti; John C Byrd; Kanti R Rai; Jennifer R Brown; Andrew W Greaves; Jeanette Eckel-Passow; Donna Neuberg; Thomas J Kipps; Gordon W Dewald
Journal:  Cancer Genet Cytogenet       Date:  2010-12

4.  Biological evaluation of CpG stimulation of normal human B-cells: implications for B-cell biology and cytogenetic analysis of CLL B-cells.

Authors:  Xiaosheng Wu; Stephanie A Smoley; Mark A Peterson; Denise K Walters; Bonnie K Arendt; Grzegorz S Nowakowski; Daniel L Van Dyke; Neil E Kay; Diane F Jelinek
Journal:  Br J Haematol       Date:  2011-02-17       Impact factor: 6.998

5.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Nicole Weit; Nils Lilienthal; Michael Hallek; Michael J Keating; Dan Jones
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

6.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

7.  Submicroscopic deletions of immunoglobulin heavy chain gene (IGH) in precursor B lymphoblastic leukemia with IGH rearrangements.

Authors:  Jungwon Huh; Yeung Chul Mun; Eun Sun Yoo; Chu Myong Seong; Wha Soon Chung
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.